Accuray Asia Ltd. will work with Tianjin-based CNNC High Energy Equipment, a subsidiary of China Isotope and Radiation (HKSE:01763). CNNC will own 51% of the joint venture, known as CNNC Accuray (Tianjin) Medical Technology, and Accuray’s subsidiary will own the rest.
The companies’ leaders believe they will be uniquely positioned to serve the world’s largest growth market for radiation oncology systems by helping to meet critical market demand as stipulated by the Ministry of Health of the People’s Republic of China, as well as by addressing longer-term unmet needs.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!